Clinical Research on Effects of Valsartan on Patients with Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation

QIAN Jin,CAI Xiaoli,YANG Bo

DOI: https://doi.org/10.3969/j.issn.1671-8852.2006.04.033

2006-01-01

Abstract:Objective: To study the effects of valsartan on patients with essential hypertension(EH) complicated with paroxysmal fibrillation(PAF) and its mechanism.Methods: Eighty-four patients with EH complicated with PAF were divided randomly into valsartan group and control group.The patients in valsartan group took valsartan 50-100 mg per day orally,and took diuretics if necessary.The patients in control group took duretics and/or amlodipine orally. All the patients were followed up to record the onset of AF,and in 6,12,18,24 months later,the inner diameter of left atrium were measured by echocardiogram.Results: Thirty-eight patients in valsartan group and 37 patients in controlled group finished the study.The onsets of AF in controlled group during 6-12 and 12-18 months were not significantly changed,while in 18-24 months were increased significantly compared with pre-treatment and valsartan group(P0.05).In valsartan group,the onset of AF during 6-12 and 12-18 months were not significantly changed and increased during 18-24 months.The inner diameter of left atrium in controlly group at the 6th and 12th month were not significantly changed and at the 24th month was significantly enlarged(P0.05).The inner diameters of left atrium in valsartan group were not changed after treatment.Conclusion: Valsartan can prevent the enlargement of atrium of patients with EH complicated with PAF,and reduce the onsets of AF.